MX2022001520A - Composiciones y metodos para mejorar activacion de receptor de opioide por hexadienoatos opioides y hexadienoatos opcionalmente sustituidos. - Google Patents

Composiciones y metodos para mejorar activacion de receptor de opioide por hexadienoatos opioides y hexadienoatos opcionalmente sustituidos.

Info

Publication number
MX2022001520A
MX2022001520A MX2022001520A MX2022001520A MX2022001520A MX 2022001520 A MX2022001520 A MX 2022001520A MX 2022001520 A MX2022001520 A MX 2022001520A MX 2022001520 A MX2022001520 A MX 2022001520A MX 2022001520 A MX2022001520 A MX 2022001520A
Authority
MX
Mexico
Prior art keywords
hexadienoates
opioid
hexadienoate
modification
compositions
Prior art date
Application number
MX2022001520A
Other languages
English (en)
Spanish (es)
Inventor
Georgiy Nikonov
Levon Isakulyan
Michael V Voronkov
Original Assignee
Kappa Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/540,058 external-priority patent/US11186585B2/en
Application filed by Kappa Pharma Llc filed Critical Kappa Pharma Llc
Publication of MX2022001520A publication Critical patent/MX2022001520A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/20Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C219/22Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22Bridged ring systems
    • C07D221/26Benzomorphans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22Bridged ring systems
    • C07D221/28Morphinans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08Oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2022001520A 2019-08-11 2020-03-07 Composiciones y metodos para mejorar activacion de receptor de opioide por hexadienoatos opioides y hexadienoatos opcionalmente sustituidos. MX2022001520A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962885311P 2019-08-11 2019-08-11
US16/540,058 US11186585B2 (en) 2018-08-17 2019-08-14 Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates
PCT/US2020/021599 WO2021029914A1 (en) 2019-08-11 2020-03-07 Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates

Publications (1)

Publication Number Publication Date
MX2022001520A true MX2022001520A (es) 2022-07-21

Family

ID=74571142

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001520A MX2022001520A (es) 2019-08-11 2020-03-07 Composiciones y metodos para mejorar activacion de receptor de opioide por hexadienoatos opioides y hexadienoatos opcionalmente sustituidos.

Country Status (6)

Country Link
EP (1) EP4010078A4 (https=)
JP (1) JP7535569B2 (https=)
CN (1) CN114828961B (https=)
CA (1) CA3149152A1 (https=)
MX (1) MX2022001520A (https=)
WO (1) WO2021029914A1 (https=)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
EP0615756B1 (en) * 1993-03-15 2001-06-27 National Science Council Nalbuphine esters and long-acting pharmaceutical compositions containing them
CN1050130C (zh) 1997-07-04 2000-03-08 卢正堂 纳洛酮酸脂和纳屈酮酸脂及系列物和制备方法
ES2188481T3 (es) 2000-04-27 2003-07-01 Oliver Yoa-Pu Hu Derivados de polinalbufina.
TWI226239B (en) 2000-05-15 2005-01-11 You-Pu Hu Novel oral pharmaceutical composition containing nalbuphine ester prodrug
CA2771263A1 (en) 2000-07-27 2002-02-07 Rutgers, The State University Therapeutic polyesters and polyamides
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US7759358B2 (en) 2003-07-23 2010-07-20 Crooks Peter A Oral bioavailable prodrugs
US20050137141A1 (en) 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
EP1928881A2 (en) 2005-08-19 2008-06-11 Pharmacofore, Inc. Prodrugs of active agents
US20090186832A1 (en) 2008-01-18 2009-07-23 Shire Llc Amino acid peptide pro-drugs of phenolic analgesics and uses thereof
EP2413937A1 (en) 2009-04-02 2012-02-08 Shire LLC Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
AU2010272233A1 (en) 2009-07-17 2012-02-09 Shire Llc Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
EP2628489B1 (en) * 2009-07-21 2017-03-01 Nektar Therapeutics PEG oligomer-fentanyl conjugates
US20110190267A1 (en) * 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
US8461171B2 (en) * 2010-02-09 2013-06-11 QRxPharma Ltd. Hybrid opioid compounds and compositions
EP2552924B1 (en) * 2010-04-02 2015-09-16 Zynerba Pharmaceuticals, Inc. Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
AR084620A1 (es) * 2010-12-28 2013-05-29 Euro Celtique Sa Una combinacion de un agonista opiaceo y un antagonista opiaceo en el tratamiento de la enfermedad de parkinson
US10017519B2 (en) * 2015-04-27 2018-07-10 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof
US9987269B2 (en) * 2015-04-27 2018-06-05 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of oxymorphone and uses thereof
US10449190B2 (en) * 2015-04-27 2019-10-22 John K. Thottathil Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof
US9974858B2 (en) * 2015-08-29 2018-05-22 Medrx Co., Ltd Percutaneous absorption composition
US12590065B2 (en) * 2017-04-14 2026-03-31 Zevra Therapeutics, Inc. Levorphanol prodrugs and processes for making and using them
US11186585B2 (en) * 2018-08-17 2021-11-30 Kappa-Pharma LLC Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates

Also Published As

Publication number Publication date
JP7535569B2 (ja) 2024-08-16
CA3149152A1 (en) 2021-02-18
JP2022544564A (ja) 2022-10-19
EP4010078A4 (en) 2023-08-09
WO2021029914A1 (en) 2021-02-18
EP4010078A1 (en) 2022-06-15
CN114828961A (zh) 2022-07-29
CN114828961B (zh) 2024-03-29

Similar Documents

Publication Publication Date Title
WO2004054511A3 (en) Analgesic combination comprising nalbuphine
MX2009011958A (es) Compuestos de morfina.
MX361542B (es) Compuestos de morfinan.
SI1554282T1 (sl) Derivati morfinana, substituirani v legi 14 in njihove kvarternarne amonijeve soli, postopek izdelave in uporaba
RU2009125597A (ru) Пролекарства и способы их получения и применения
MX2009010378A (es) Metodos para tratar o prevenir el vomito utilizando secretagogos de hormona de crecimiento.
YU98902A (sh) Derivati aza premošćenih bicikličnih amino kiselina kao antagonisti alfa4 integrina
MXPA05003104A (es) Hidromorfonas n-sustituidas y uso de las mismas.
IL164787A0 (en) Tachykinin receptor antagonists
IL166298A0 (en) 8-hydroxy quinoline derivatives
UA96777C2 (ru) Фенилпропионамидные соединения и их применение как опиоидных агонистов
UA89192C2 (ru) Производные пиролопиримидина и пиролопиридина, замещенные циклической аминогруппой, как антагонисты crf
HRP20130614T1 (en) Novel pyrazole-substituted arylamides
EA030609B8 (ru) Композиции бупренорфина и антагонистов мю-опиоидных рецепторов
PL1828177T3 (pl) Nowi antagoniści receptora MCH
WO2005040157A3 (en) Novel mch receptor antagonists
MX2009008561A (es) Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.
MX2012011216A (es) Antagonista del receptor opioide para usarse en el tratamiento de la enfermedad herpes zóster.
MX2022001520A (es) Composiciones y metodos para mejorar activacion de receptor de opioide por hexadienoatos opioides y hexadienoatos opcionalmente sustituidos.
MX385316B (es) Compuestos de morfinano.
EP4616915A3 (en) Ecopipam for treatment of tourettes syndrome
MXPA05011993A (es) Compuestos de pirrolo[1,2-b]piridazina.
WO2001046198A3 (en) Nonpeptide kappa opioid receptor antagonists
MX341177B (es) Compuestos de morfina.
EA015500B9 (ru) Новые антагонисты мсн рецепторов